Here we refined an existing method to generate tight vessels, by differentiating hESCs in CD34 + Vascular Progenitor Cells (VPCs), using chemically defined media and growth conditions. We selectively purified these cells from CD34 -outgrowth populations also formed. To analyze these differentiation processes, we compared the proteomes of the hESCs with those of the CD34 + and CD34 -populations, using high resolution mass spectrometry, label-free quantification and multivariate analysis. 18 protein markers validate the differentiated phenotypes in immunological assays; 9 of these were also detected by proteomics and show Data are available via ProteomeXchange with identifier PXD003606.
Introduction
Regenerative Medicine (RM) is an emerging interdisciplinary field of research and clinical applications, focused on the repair, replacement, or regeneration of cells, tissues, or organs to restore impaired function resulting from any cause, including congenital defects, disease, and trauma. 1 Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), created by reprogramming adult donor cells, have the ability to differentiate into any human cell and ultimately to generate any human tissue. [2] [3] [4] However, main challenges in RM are the ability to reproducibly differentiate hESCs/iPCSs to a specific cell type and the creation of vascular tissue to ensure rapid in vivo vascularization and sufficient nutrient flow to the implant inside the host. [5] [6] [7] [8] In addition, RM protocols require compliance with the GMP (Good Manufacturing Practice) specifications necessitating chemically defined media to avoid use of serum or feeder layers, ensuring that the cells have been produced according to predefined manufacturing criteria. 9 Current interest has shifted towards generating tissue-engineered constructs that are already vascularized before implantation. 10 For the differentiation process, cells are grown on biodegradable 3D scaffolds, which mimic cell-cell or cell-matrix interactions. In addition, soluble factors are mimicking the physiological microenvironment leading to differentiation of hESCs to Vascular Progenitor Cells (VPCs). Differentiation of VPCs from their precursor cells involves co-operative interaction among many different signaling molecules [i.e. hedgehog, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), bone morphogenetic protein (BMP), Notch, Wnt], and transcription factors (ETS, Forkhead, GATA transcription factors). 11, 12 A thorough understanding of the molecular events that underlie this differentiation process is still missing as are comprehensive biomarker signatures with which to monitor both the transition as well as the biological robustness of the final differentiated states. 13 6
Omics workflows provide powerful means for the study of the molecular base of the differentiation process of VPCs, due to their ability to monitor multiple targets (genes/proteins) simultaneously, in complex samples. Several RNA-based omics approaches have been used for the study of vascular progenitor cell differentiation. [14] [15] [16] [17] [18] [19] However, mRNA expression levels are not necessarily correlated with protein abundance. 20 Hence proteomics approaches are essential to directly analyze the expressed proteome shifts that occur during differentiation events and the concomitant post-translational and complexome changes. 21 To our knowledge, there are no proteomics analyses in the literature of VPCs derived from human pluripotent SCs, in defined culture conditions. Several analyses have been performed in ESCs or iPSCs 22 , in primary endothelial cells after stimulation with VEGF
23
, or in in vitro differentiated erythroid cells derived from iPSCs. [23] [24] [25] Endothelial cells display functional heterogeneity that cannot be addressed with the existing markers for cell classification. 13 Therefore, there is intense need to identify more VPCs markers 26, 27 , which can be used to monitor this population. Proteomics can be a major contributor in the development of proteomic signatures of VPCs.
Here, we modified and refined an existing method in order to generate VPCs that could be used to generate tight vessels. hESCs were first differentiated to mesodermal intermediates and then towards Vascular Progenitor cells (VPCs). Each growth factor is added separately, for better control over the differentiation process and offers the possibility to study each step separately. In addition, the protocol is fast, providing functional VPCs within 5 days. The differentiation event gives rise to two distinct cellular populations: the CD34 + VPCs and a CD34 -population that probably contains mixed cells (see below), that can be further differentiated into other cell types such as other mesoderm derivatives including cells from the mesenchymal lineage. 28 We monitored these cell states by comparing the proteome of the initial hESCs with the differentiated CD34 + and CD34 -populations, using high resolution mass 
Differentiation of hESCs
Differentiation of hESCs to CD34 + cells was carried out under feeder-free, chemically defined conditions as described with minor modifications (Fig. 1A) . 28 Briefly, H1 colonies were first dissociated into small clumps and re-plated onto Matrigel-coated 6-well plates as per normal routine passaging. After 48 h, mTeSR medium was changed to differentiation medium (APEL), which was synthesized as previously described 
LC-MS/MS analysis
Lyophilized peptide samples were first dissolved in an aqueous solution containing 0.1% v/v formic acid (FA) and 5% v/v ACN and afterwards were analyzed using nano-Reverse Phase LC coupled to a Q Exactive™ Hybrid Quadrupole -Orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany) through a nanoelectrospray ion source (Thermo Scientific, Bremen, Germany). Peptides were initially separated using a Dionex UltiMate 3000 UHPLC system on an EasySpray C18 column (Thermo Scientific, OD 360 µm, ID 50 µm, 15 cm length, C18 resin, 2 µm bead size) at a nanoLC flow rate of 300 nL min A 60 min 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 10 multi-step gradient was used from Buffer A to Buffer B (percentages from each in parentheses below) as follows: 0-3 min constant (96:4), 3- The separated peptides were analyzed in the Orbitrap QE operated in positive ion mode (nanospray voltage 1.5 kV, source temperature 250°C). The instrument was operated in datadependent acquisition (DDA) mode with a survey MS scan at a resolution of 70,000 FWHM for the mass range of m/z 400-1600 for precursor ions, followed by MS/MS scans of the top 10 most intense peaks with +2, +3 and +4 charged ions above a threshold ion count of 16,000 at 35,000 resolution. MS/MS was performed using normalized collision energy (NCE) of 25%
with an isolation window of 3.0 m/z, an apex trigger 5-15 sec and a dynamic exclusion of 10 s.
Data were acquired with Xcalibur 2.2 software (Thermo Scientific).
MS data analysis
Raw MS files from the mass spectrometer were analyzed by MaxQuant v1.5.2.8, a quantitative proteomics software package designed for analyzing large mass spectrometric data sets.
31 MS/MS spectra were searched by the Andromeda search engine against the Uniprot human reviewed proteome without isoforms (Last modified -July 6, 2015, 20,198 proteins) and common contaminants as described. 32 Enzyme specificity was set to trypsin, allowing for a maximum of two missed cleavages. Dynamic (methionine oxidation and N-terminal acetylation) and fixed (S-Carbamidomethylation of cysteinyl residues) modifications were selected. Precursor and MS/MS mass tolerance was set to 20 ppm for the first search (for the identification of maximum number of peptides for mass and retention time calibration) and 4.5 ppm for the main search (for the refinement of the identifications 
Multivariate statistical Analyses
For the identification of differentially synthesized proteins we performed multivariate analysis using the Partial Least Square regression (PLS) method (n = 6). 35, 36 We constructed a PLS model using the LFQ intensities of the whole dataset, derived from the three populations (hESCs, CD34 + and CD34 -cells). Most significant variables were selected after performing
Variable Importance in Projection analysis (VIP). 37 For the non-identified proteins, the quantitative value was set to 0. The 250 most significant proteins, based on the VIP analysis, were then tested for statistically significant difference in abundance. Since our data does not necessarily follow the assumptions of normally distributed data of equal variance, we performed the non-parametric test Kruskal-Wallis (p-value <0.05), on LFQ intensities to select proteins of possible interest. Pairwise differences were then examined using the Wilcoxon test (p-value <0.05).
Other software
Images and vectors were processed using Canvas (ACDSee). Statistical analysis was performed using STATISTICA v8 (Statsoft) or R scripts, and graphs were plotted in R using ggplot2 package or in Prism v5 (GraphPad 
Results

Differentiation of hESCs to CD34 + Vascular Progenitor Cells
Differentiation of hESCs to vascular progenitor cells was conducted in a chemically defined stepwise approach, using a modified protocol from Tan et al. 28 Pluripotent stem cells were first induced to mesoderm using a GSK inhibitor and BMP4 and then to vascular indicating that stimulation with VEGF is an essential step for the differentiation process. Since CD34 has generally been associated with progenitors of endothelial lineages, we isolated the CD34 + cells using magnetic beads coated with anti-CD34 antibody (Fig. 1C) .
First, we assessed the endothelial potential of the isolated hESC-derived CD34 + cells by testing them for tube formation on 3D Matrigel cultures. Indeed, the sorted CD34 + fraction (but not the CD34 -fraction) could be organized into vascular-like structures on a Matrigel support (Fig. 1D) . Quantitative RT-PCR analyses showed that CD34 + cells expressed typical endothelial markers such as the genes encoding VEGF receptors (VEGFR 1,2,3; neuropillin 1, 2), CD31
(PECAM1), VE-Cadherin (CDH5), Tie2 (TEK) 38 , the arterial endothelial marker EPHRINB2 (EFNB2) 39 and the venous endothelial marker EPHRINB4 (EFNB4) 40 (Supporting Fig. S-1F ).
Also ETV2, a transcription factor belonging to the ets-transcription family, which is important for the commitment to the endothelial lineage, during development, [41] [42] [43] [44] [45] was upregulated (Supporting Fig. S-1F Proteoglycan NG2 (NG2/CSPG4) was negligible (Supporting Fig. S-1F ).
To 
Proteomic analysis of pluripotent hESCs, CD34 + and CD34 -cells
We first compared the proteomic profile of hESCs with that of the CD34 + and CD34 -populations (see Experimental Section). To exclude proteins with less reliable quantification, from the total number of proteins identified we proceeded for further analysis using the ones that were quantified using two peptides. In total, 4491 proteins were quantified, in all groups, at least once (Supporting Table S -2). Label-free quantification reproducibility between the biological repeats, is good for the specific workflow setup that was followed, with average
Pearson correlation r 2 = 0.86 between biological repeats of the same group and r 2 = 0.83, between groups (Supporting Fig. S-3A ). Protein copy numbers in the cell span roughly in a range of seven orders of magnitude. 48 Given the similarity between different cell types 49, 50 , we approximated the abundance of the proteins identified here based on a reference set by aligning 14 the experimentally identified proteins of this study with those of the reference one (Supporting
Fig. S-3B)
. 48 Proteins present in low copy numbers are also identified here, suggesting good identification depth.
Next, we sought out differentially synthesized proteins by performing multivariate analysis.
Due to the nature of the proteomics data (small number of samples (n) and large number of variables -proteins (p)), we implemented Partial Least Squares regression (PLS) to identify possible proteins of interest 35, 51 , using the LFQ-derived abundance values of the identified proteins. To select the proteins that show the greatest variation in our dataset, we combined PLS analysis with the Variable Importance in Projection (PLS-VIP) method. 36, 37 By plotting the scores of the PLS model, we observe 3 distinct clusters corresponding to the 6 biological repeats of each of the three different cell populations examined ( Fig. 2A) . Also, the variation between the biological repeats is smaller in hESCs and CD34 + cells types compared to that in the CD34 -cells, which are considered to be a mixed population of several other progenitors. To find proteins with differential abundance, we then used the VIP method to identify the proteins with the highest variation. The 250 proteins that contribute most to the variation were then tested for statistical significance. Since we cannot consider that the proteomics quantification approach that we use, follows the assumptions of normality or equal variance between the different study groups, we used the non-parametric test Kruskal-Wallis (p-value < 0.05) followed by post hoc analysis using the Wilcoxon test (p-value < 0.05). 236 proteins showed differential synthesis in at least one pair ( 
Validation of proteomics results using established protein markers
To validate the quantification approach of our proteomics workflow, we assessed the expression of selected markers in hESCs and in their derived differentiated populations, using immunofluorescence (IF), western blot analysis (WB) and flow cytometry (FACS). Loss of pluripotency during this differentiation procedure was evidenced by the down-regulation of 
GO-slim analysis of the differential proteins
To gain functional insight in the proteins identified by the proteomics flow, we performed limited scale Gene Ontology analysis (GO-slim) 58 for the differential proteins in the three cell populations (hESCs, CD34 + VPCs and CD34 -). Proteins specific to each group (see Experimental Section), were uploaded separately in the AmiGO server and tested for selected 
Pathway Enrichment Analysis
We then sought to determine differentially activated pathways between hESCs and CD34 + /CD34 -cells in our experimental dataset. For this we used WebGestalt, an in silico tool for functional annotation, which incorporates information from different public resources for the biological interpretation of the omics data. 61, 62 Differentially synthesized proteins from hESCs, CD34 + and CD34 -cells were uploaded as one dataset in WebGestalt (Supporting Table S-3) .
Enrichment was performed in pathways included in the publicly curated database Wikipathways (see Supporting Experimental Procedures). Annotation enrichment could identify fifteen pathway terms that were statistically over-represented within the list of the differential proteins from all three cell populations (Table 1 ). These pathways represent: i) adhesion and mechanotransduction, ii) signaling and iii) regulation or metabolism.
Manual curation of the proteomics results -Cell characterization
As a next step to improve our understanding about the phenotype of the three cell populations analyzed here, we checked manually for references of the differentially synthesized Table S 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
Discussion
Cell-based vascular engineering to regenerate and remodel damaged or structurally abnormal vessels, and the affected tissues thereof, constitutes an important area of research requiring further basic research before clinical translation. Regenerating tissues over 100-200 µm exceeds the capacity of nutrient supply and waste removal by diffusion, thus requiring an intimate supply of vascular networks 7, 8 to ensure survival of the implant in vivo. 64 Prevascularized tissue-engineered constructs (TECs) consisting of mature vessels should be able to connect in a very short time to the vessels of the host providing immediate blood supply to the TEC. Despite the abundance of preclinical animal studies [65] [66] [67] , there are still incomplete data and a lack of concrete guidelines concerning the generation of pre-vascularized TECs for preclinical evaluation. However, the current use of vascular cells differentiated from hESC/hiPSC are superior to the adult stem cell-derived VPCs. This is due to the higher proliferative potential and plasticity, because scaling TECs to human size requires maintaining constant physical conditions and cellularity over larger dimensions.
An important issue in vessel regeneration is the initial source of the cells to be used in therapeutic approaches. Generation of engineered vessels was achieved using a vast spectrum of 51 The 250 proteins showing the most variation between the groups, were selected using the VIP method 37 , and further validated using the non-parametric test Kruscal-Wallis. Nine of the markers tested during immunophenotyping were also detected by proteomics in the differentially abundant proteins, thus validating our proteomics flow. Among the possible proteins of interest, 63 present in CD34 + or CD34 -could be assigned to known biological functions related to vasculogenesis, providing a broad view of this differentiation event and enhancing previous hypothesis. In addition, we identify >150
proteins showing differential abundance that might help in the understanding of the mechanism of vasculogenesis, or could provide possible differentiation markers (Supporting Table S -4) . signaling complex being a critical regulator of vascular development. 76 The newly identified proteins that are co-synthesized together with CD34 and the other known markers of endothelial commitment may contribute to a more accurate characterization of this vascular progenitor cell population in future studies.
In CD34 + cells seven proteins that have been reported to be expressed in immature smooth muscle cells and play a role in vascular mural cell differentiation and function show increased abundance (PALD1, HDAC7, TLN1, VASP, CRIP2, LMNA, CORO1C) (Supporting Table S 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 when we cultured CD34 + cells with PDGFβ/TGFβ they exhibited a characteristic fibroblast-like morphology, they lost the expression of CD31 and up-regulated the mural marker SM22-alpha (Supporting Fig. S-2B ). Thus, when fully de novo vessels are required, both VEGF and PDGF will have to be used to treat isolated CD34 + progenitors from hiPSC patients, similarly to what was done to the hESC-derived CD34 + progenitors of the present study. This treatment would drive the differentiation to new tight vessels that have both cell types in the correct proportion.
In contrast, in diabetic retinopathy where the main abnormality is the lack of pericytes, then the CD34 + progenitor cell (cultured on the correct scaffold) together with PDGF could be sufficient to remodel the damaged retina.
78
Several cytoskeleton-related proteins are enriched in CD34 + cells (Fig. 4D , Supporting 84 and/or the formation of tight bundles of synchronously polymerizing actin filaments by the leading edge filopodia with the participation of VASP proteins, which are also oversynthesised 85 (Fig. 5, right panel) . ERM proteins, such as Ezrin, localize to the apical surfaces of many cells and are essential for establishing apical identity. Moreover, they are able to orient 
Conclusion
In conclusion, by modifying an established method, we differentiated hESCs to distinct CD34 + and CD34 -cells that could be segregated from each other. CD34 + cells were induced to differentiate towards the endothelial lineage by VEGF, as evidenced by validation using known markers and functional characterization (Fig. 5I) , whereas PDGF/TGFβ1 induced the expression of mural cell (SMCs/PCs) markers (Fig. 5II) (Fig. 5II) . However, the pattern of over-synthesized proteins in CD34 -cells is consistent with differentiation to the mesenchyme-direction that consist of skeletal myogenic /osteogenic/chondrogenic/adipogenic lineages (Fig. 5III) . The identified proteins due to the rigorous criteria used may serve as markers for further characterization of subpopulations of these cells in future studies. 
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Figure 2. Proteomics analysis workflow
In the present study we performed a proteomic characterization of pluripotent hESCs and the two differentiated cell populations of CD34 + VPCs and CD34 -cells using high resolution mass spectrometry combined with label-free quantification and multivariate analysis. 6
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